Skip to main content
. 2021 Jun 14;21:567. doi: 10.1186/s12879-021-06237-x

Table 1.

Baseline characteristics of the study population

Parameters TAF 25 mg TDF 300 mg ETV 0.5 mg P value
(n = 10) (n = 10) (n = 20)
Age (years) 40.56 ± 11.18 41.00 ± 12.64 39.72 ± 9.13 0.901
Male, n (%) 10 (100) 10 (100) 20 (100) 1.0
Liver cirrhosis 8 (80) 7 (70) 13 (65) 0.901
ALT (U/L) 351.10 (308.72) 203.67 (173.61) 385.85 (519.33) 0.588
AST (U/L) 263.78 (242.47) 156.89 (84.39) 382.61 (397.06) 0.707
TBIL (μmol/L) 362.93 (178.62) 321.10 (127.87) 240.44 (144.35) 0.174
Albumin (g/L) 31.32 (3.71) 30.90 (4.38) 32.23 (4.19) 0.905
Urea (mmol/L) 5.71 (3.09) 5.74 (2.70) 5.86 (3.23) 0.948
Creatinine (μmol/L) 77.22 (34.20) 66.22 (22.08) 66.00 (24.27) 0.458
eGFR (mL/min/1.73m2) 112.76 (41.47) 150.23 (30.12) 112.34 (68.85) 0.274
INR 1.71 (0.32) 2.08 (0.87) 2.13 (0.63) 0.179
WBC (× 109/L) 6.22 (1.82) 7.28 (3.48) 6.91 (3.54) 0.819
PLT (×109/L) 115.11 (60.48) 97.44 (113.02) 98.33 (63.09) 0.168
Serum sodium, mmol/L 137.11 (2.32) 135.11 (4.96) 135.16 (7.06) 0.784
HbeAg positive 8 (80) 8 (80) 15 (75) 0.931
LogHBV DNA (log IU/mL) 4.80 (1.93) 5.81 (1.87) 5.13 (1.89) 0.458
MELD score 21.56 (5.66) 21.33 (7.28) 20.50 (5.40) 0.943
CTP score 10.22 (1.44) 10.78 (1.64) 10.44 (1.56) 0.151
CTP class(B/C) 3/7 1/9 1/19 0.202
NUC-naïve 7 (70) 2 (20) 15 (75) 0.019
Follow-up (wk) 68.50 (48–92) 64.50 (51–95) 69.00 (50–95) 0.938

Data are expressed as mean ± standard deviation (SD), number (percentage) or median (range)

ETV entecavir, TDF tenofovir disoproxil fumarate, TAF tenofovir alafenamide, ALT alanine aminotransferase, AST aspartate Aminotransferase, TBIL total bilirubin, INR international normalized ratio, WBC white blood cell count, PLT platelet count, HBeAg Hepatitis B e antigen, HBV hepatitis B virus, MELD Model for End-stage Liver Disease, CTP Child-Turcotte-Pugh, NUC nucleos(t) ide analogues